Effect of beta-glucan supplementation on cystic fibrosis colonic microbiota: an in vitro study.

Autors de IIS La Fe

• Etna Masip Simó

  Autor

• 

  Carmen Ribes Koninckx

  Autor

• Joaquin Calvo Lerma

  Autor

Autors aliens a IIS La Fe

• Asensio-Grau, Andrea
• Heredia, Ana
• Garcia-Hernandez, Jorge
• Cabrera-Rubio, Raul
• Collado, Maria Carmen
• Andres, Ana

Grups d'Investigació

• Enfermedad celíaca e Inmunopatología digestiva

  

  Leader

  Carmen Ribes Koninckx

• Unidad Mixta De Investigación en Nutrición de Precisión para patologías digestivas (NUTRICURA PDig)

  

  Leader

  Carmen Ribes Koninckx

Abstract

BACKGROUND: Children with cystic fibrosis (CF) present with gut dysbiosis, and current evidence impedes robust recommendations on the use of prebiotics. This study aimed at establishing the prebiotic potential of a commercial beta-glucan on the in vitro colonic microbiota of a child with CF compared to a healthy counterpart (H). METHODS: A dynamic simulator of colonic fermentation (twin-SHIME model) was set up including the simulation of the proximal (PC) and distal colon (DC) of the CF and the H subjects by colonizing the bioreactors with faecal microbiota. During two weeks the system was supplied with the beta-glucan. At baseline, during treatment and post-treatment, microbiota composition was profiled by 16S rRNA and short-chain fatty acids (SCFA) production was determined by GS-MS. RESULTS: At baseline, Faecalibacterium, was higher in CF' DC than in the H, along higher Acidaminococcus and less Megasphaera and Sutterella. Beta-glucan supplementation induced increased microbiota richness and diversity in both subjects during the treatment. At genus level, Pseudomonas and Veillonella decreased, while Akkermansia and Faecalibacterium increased significantly in CF. CONCLUSION: The supplementation with beta-glucan suggests positive results on CF colonic microbiota in the in vitro context, encouraging further research in the in vivo setting. IMPACT: Current evidence supports assessing the effect of prebiotics on modifying cystic fibrosis microbiota. The effect of beta-glucan supplementation was evaluated in a controlled dynamic in vitro colonic ecosystem. Beta-glucan supplement improved diversity in cystic fibrosis colonic microbiota. The treatment showed increased abundance of Faecalibacterium and Akkermansia in cystic fibrosis. New evidence supports the use of prebiotics in future clinical studies.

© 2023. The Author(s), under exclusive licence to the International Pediatric Research Foundation, Inc.

Keywords

• CHAIN FATTY-ACIDS; GUT MICROBIOTA; FECAL MICROBIOTA; DIVERSITY; IMPACT; DYSBIOSIS